Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Assets (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Current Assets data on record, last reported at $42.5 million in Q4 2025.

  • For Q4 2025, Current Assets fell 16.88% year-over-year to $42.5 million; the TTM value through Dec 2025 reached $42.5 million, down 16.88%, while the annual FY2025 figure was $42.5 million, 16.88% down from the prior year.
  • Current Assets reached $42.5 million in Q4 2025 per VRCA's latest filing, up from $36.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $102.0 million in Q1 2021 and bottomed at $28.2 million in Q3 2024.
  • Average Current Assets over 5 years is $59.5 million, with a median of $57.1 million recorded in 2022.
  • Peak YoY movement for Current Assets: skyrocketed 111.37% in 2023, then tumbled 69.27% in 2024.
  • A 5-year view of Current Assets shows it stood at $74.3 million in 2021, then tumbled by 47.38% to $39.1 million in 2022, then soared by 98.21% to $77.5 million in 2023, then tumbled by 33.99% to $51.2 million in 2024, then decreased by 16.88% to $42.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $42.5 million in Q4 2025, $36.3 million in Q3 2025, and $36.8 million in Q2 2025.